Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected Subjects | Zendy

Daniel R. Kuritzkes | Zendy; Christina M. Lalama | Zendy; Heather J. Ribaudo | Zendy; Michelle Marcial | Zendy; William A. Meyer | Zendy; Cecilia M. Shikuma | Zendy; Victoria A. Johnson | Zendy; Susan A. Fiscus | Zendy; Richard T. D’Aquila | Zendy; Bruce R. Schackman | Zendy; Edward P. Acosta | Zendy; Roy M. Gulick | Zendy

Open Access

Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected Subjects

Author(s) -

Daniel R. Kuritzkes,

Christina M. Lalama,

Heather J. Ribaudo,

Michelle Marcial,

William A. Meyer,

Cecilia M. Shikuma,

Victoria A. Johnson,

Susan A. Fiscus,

Richard T. D’Aquila,

Bruce R. Schackman,

Edward P. Acosta,

Roy M. Gulick

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/528802

Subject(s) - efavirenz , medicine , cohort , reverse transcriptase inhibitor , hazard ratio , regimen , hiv drug resistance , confidence interval , cohort study , viral load , drug resistance , virology , human immunodeficiency virus (hiv) , biology , antiretroviral therapy , microbiology and biotechnology

A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as assessed by viral genotyping, on the response to efavirenz-containing regimens in AIDS Clinical Trials Group A5095. The sample included a random cohort of efavirenz-treated subjects plus unselected subjects who experienced virologic failure. Of 220 subjects in the random cohort, 57 (26%) had virologic failure. The prevalence of baseline NNRTI resistance was 5%. The risk of virologic failure for subjects with baseline NNRTI resistance was higher than that for subjects without such resistance (hazard ratio 2.27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research